Autoantibodies occur in many different nervous system disorders, and are increasingly being found in disorders not traditionally associated with the immune system. Determining if the autoantibodies play a functional or pathogenic role is critical in selecting the most appropriate treatment options.
Browsing: Cognitive/neurodegenerative disorders
The study from researchers at Michigan State University (MI, USA) also demonstrates that an antihistamine is effective in preventing prion aggregation.
This article examines a number of different disease-modifying therapy strategies for the treatment of relapsing-remitting multiple sclerosis.
Milan Fiala and Matteo Pellegrini review current research that indicates a role for omega-3 fatty acids in slowing the progression of mild cognitive impairment.
This review provides a comprehensive overview of miRNAs as biomarkers and therapeutic targets for neurodegenerative disorders.
New research indicates that drops in blood pressure when standing up could increase the likelihood of developing cognitive decline and dementia in later years.
In this edition of NCTalks, we speak to Robyn Klein as part of our Spotlight on neuroimmunology – Robyn discusses her research, how inflammatory processes contribute to neurologic disease, and whether immunology and inflammation could be the basis of an eventual preventative treatment for neurodegenerative disease.
Lauren Pulling speaks to Bart De Strooper about his role as the Director of the new UK Dementia Research Institute and his vision for this exciting new venture.
A researcher’s own experiences have led to further understanding of the repair process needed for multiple sclerosis.
Researchers at Colombia University, New York (NY, USA), have recently demonstrated that tau pathology induces dysfunction in cells specifically tuned to compute spatial information.